{"title":"胰高血糖素样肽- 1受体激动剂exendin - 4可改善Wistar京都大鼠肠易激综合征模型的胃肠功能障碍","authors":"Rebecca O’Brien, D. O’Malley","doi":"10.1111/nmo.13738","DOIUrl":null,"url":null,"abstract":"Glucagon‐like peptide‐1 (GLP‐1) is beneficial in relieving pain‐related symptoms of Irritable bowel syndrome (IBS), a prevalent, multi‐factorial functional bowel disorder characterized by diarrhea and/or constipation, abdominal bloating, and pain. Activation of myenteric neurons has been implicated in the inhibitory effects of GLP‐1 on gastrointestinal motility; however, the mechanisms of action underlying this are not clear.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":"{\"title\":\"The Glucagon‐like peptide‐1 receptor agonist, exendin‐4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome\",\"authors\":\"Rebecca O’Brien, D. O’Malley\",\"doi\":\"10.1111/nmo.13738\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glucagon‐like peptide‐1 (GLP‐1) is beneficial in relieving pain‐related symptoms of Irritable bowel syndrome (IBS), a prevalent, multi‐factorial functional bowel disorder characterized by diarrhea and/or constipation, abdominal bloating, and pain. Activation of myenteric neurons has been implicated in the inhibitory effects of GLP‐1 on gastrointestinal motility; however, the mechanisms of action underlying this are not clear.\",\"PeriodicalId\":19104,\"journal\":{\"name\":\"Neurogastroenterology & Motility\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurogastroenterology & Motility\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/nmo.13738\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurogastroenterology & Motility","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/nmo.13738","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Glucagon‐like peptide‐1 receptor agonist, exendin‐4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome
Glucagon‐like peptide‐1 (GLP‐1) is beneficial in relieving pain‐related symptoms of Irritable bowel syndrome (IBS), a prevalent, multi‐factorial functional bowel disorder characterized by diarrhea and/or constipation, abdominal bloating, and pain. Activation of myenteric neurons has been implicated in the inhibitory effects of GLP‐1 on gastrointestinal motility; however, the mechanisms of action underlying this are not clear.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
